Patent · US Active

Anti-KIR combination treatments and methods

US10253095B2 · kind B2 · utility

4Cited by
11References
7Claims
0Family size

Assignees

Inventors

Key dates

Filing dateJul 15, 2011
Grant dateApr 9, 2019
Priority date
Expiry dateJul 15, 2031

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2039/505
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compositions comprising anti-KIR antibodies and one or more secondary anti-cancer agents or anti-viral agents and methods of using such combinations (as combination compositions or in separate administration protocols) in the treatment of cancers (e.g., lung cancer) or viral infection (e.g., HIV or HCV infection) are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.